Elucid Bioimaging Says Co Is Aware Of A Lawsuit Filed By Heartflow, On October 22, 2026. Elucid Will Respond To And Defend Against The Claims In The Lawsuit Through The Appropriate Legal Channels
Elucid Bioimaging Inc. ("Elucid") today reaffirmed its commitment to advancing its mission – the prediction and personalization of the prevention of heart attack and stroke – and its confidence in the technology
Elucid Bioimaging is being sued by HeartFlow over technology. The company says it will defend itself in court and keep working on its heart disease prevention mission.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.